Skip to content Skip to sidebar Skip to footer
Illustration of a giant red “848” looming over a fractured stock exchange trading floor as a trader crouches nearby, symbolizing the Dow’s decline.

U.S. stocks finished lower Tuesday, November 17, as persistent inflation, uncertainty surrounding artificial intelligence spending and a major technology earnings report kept many cautious. The Dow Jones Industrial Average fell 848.75 points, or 1.64%, while the S&P 500 declined 1.03% and the Nasdaq Composite slipped 0.74%, according to the supplied closing-market snapshot. Small-cap stocks also retreated, and the VIX volatility index rose more than 11%. The economic backdrop offered little relief. October retail sales continued to expand, but import prices rose sharply again, highlighting the Federal Reserve’s challenge of containing inflation without unnecessarily weakening demand. Meanwhile, Nvidia (NVDA) headed toward its after-hours earnings release, and new developments across enterprise AI, entertainment and biotechnology created several company-specific stories beneath the broader market decline.

Closing Market Performance

Index or assetClosing or displayed levelPoint or price changePercentage change
S&P 5007,340.53-76.06-1.03%
Dow Jones Industrial Average50,759.42-848.75-1.64%
Nasdaq Composite24,328.38-181.37-0.74%
Russell 20002,701.87-41.07-1.50%
VIX25.46+2.55+11.13%
10-year Treasury yield5.10%-0.02 as displayed-0.35%
Gold$3,855.00+$2.00+0.05%
December 2026 crude oil$85.70-$0.02-0.02%
Bitcoin$64,549.02-$692.01-1.06%

The market’s weakness extended beyond technology. Both the Dow and Russell 2000 underperformed the Nasdaq, while the VIX’s increase pointed to greater demand for protection against market swings. Gold’s modest advance contrasted with declines in stocks and bitcoin, although the limited commodity moves did not suggest a uniform rush into defensive assets.

Macroeconomic Report: Spending Holds Up, but Price Pressure Persists

Retail sales show continued demand, not a consumer collapse

U.S. retail and food services sales increased 0.2% in October to $748.2 billion, according to the Census Bureau. Sales were 6.8% above their year-earlier level. The figures are adjusted for seasonal and calendar effects, but not for inflation, an important distinction when evaluating how much of the increase represents additional purchases rather than higher prices. The report therefore offered a measured signal: households continued spending, but nominal sales growth alone does not establish equally strong growth in purchasing power. The monthly estimate also carried a margin of error of ±0.4 percentage points, reinforcing the need to avoid drawing sweeping conclusions from the headline increase. For markets, continued spending creates a policy tension. It supports business revenue and reduces immediate recession concerns, but it also gives the Fed less reason to prioritize monetary relief while inflation remains elevated.

Import prices reinforce the inflation challenge

Import prices rose 1.1% in October, matching September’s increase, according to the Bureau of Labor Statistics. Export prices also advanced 1.1%. Nonfuel import prices increased 0.8%, showing that the pressure was not confined to energy. These figures matter because higher imported input costs can squeeze business margins or eventually reach customers through higher selling prices. They do not translate automatically into an equivalent increase in consumer inflation, but consecutive large monthly gains complicate the case for a rapid easing of price pressure.

Williams pushes back on an outsized rate increase

New York Federal Reserve President John Williams indicated that inflation still requires attention while pushing back against the need for a dramatic policy move. Bloomberg reported that Williams dismissed the suggestion that the Fed needed to consider an outsized rate increase. The distinction is important: resistance to a larger increase is not the same as support for lower rates. His comments suggested a preference for a measured response, rather than an abandonment of the inflation fight. The supplied policy report also described continued concern about inflation and the possibility of further tightening. Taken together, Tuesday’s economic reports presented an uncomfortable combination for equities: demand remained resilient, imported price pressure persisted, and the Fed offered no clear signal that restrictive policy was nearing an end.

Nvidia Earnings Keep AI Expectations in Focus

After the market closed today, Nvidia beat expectations with $115.8 billion in fiscal third-quarter revenue and forecast $130.0 billion for the current quarter. The results came amid a leadership transition, regulatory scrutiny and questions about customer financing. Nvidia shares were up 1.31% in after-hours trading.

Planned IPO Tests Appetite for AI

Anthropic was reportedly likely to price its initial public offering above an indicated range of $70 to $78 per share. The supplied report said the company planned to trade under the proposed ticker ANT beginning November 19. At the time of that report, pricing was not final and trading had not begun The prospective offering created a revealing contrast with weakness in existing AI-linked shares. Demand for a new AI listing can coexist with skepticism toward established technology valuations, particularly when many are distinguishing between software adoption, computing costs and the profitability of different business models. The proposed ticker ANT should therefore be treated as a planned listing symbol, not as an already trading public security.

Disney Earnings Beat Comes With a Reporting Trade-Off

Walt Disney (DIS) reported adjusted quarterly earnings of $1.77 per share, above the $1.67 estimate cited in the supplied earnings report. Revenue increased 16% to $25.95 billion. However, an additional week in the quarter contributed approximately $0.17 to adjusted earnings per share, making the calendar effect important when evaluating underlying growth. Streaming operating income increased to $824 million from $402 million a year earlier. The additional week accounted for approximately $160 million of that improvement. Experiences operating income rose 20% to $2.25 billion, while Sports operating income increased 53% to approximately $1.4 billion. Disney (DIS) also declared a $2.00-per-share dividend, up 33% from the $1.50 paid during fiscal 2026. The company scheduled two $1.00 payments:

Record datePayment dateAmount per share
December 16, 2026January 22, 2027$1.00
June 11, 2027July 13, 2027$1.00

The dividend details were included in the company’s announcement. The reporting trade-off concerns streaming transparency. Disney (DIS) plans to stop separately reporting streaming operating income while increasing fiscal 2027 cash content spending to approximately $26 billion. That change will make broader Entertainment margins and companywide cash generation more important measures of whether additional programming spending is producing adequate returns.

Microsoft Puts Enterprise AI Costs at the Center of Ignite

Microsoft (MSFT) used its Ignite conference to emphasize specialized AI models, model selection and lower operating costs for business customers. Announcements included Microsoft IQ, MAI Code 2 and Copilot Fusion, with executives positioning the tools around company knowledge, complex coding and the coordination of multiple models. The strategic message was as important as the product list. Enterprise AI adoption increasingly depends on whether companies can deploy useful systems without allowing usage costs to rise faster than the benefits. Microsoft’s (MSFT) emphasis on task-specific models and price performance highlighted that shift. AI’s commercial opportunity is not solely about building more powerful systems. It is also about delivering useful results at a cost businesses can sustain.

Technology Outages Highlight Operational Risk

Apple (AAPL) experienced disruptions affecting services including iCloud sign-in, the App Store and Apple Pay, according to the supplied report. The company attributed the problems to an internal update rather than a cyberattack. Some services had recovered by the afternoon, although issues remained with others at the time of publication. The disruptions followed separate problems involving Microsoft (MSFT), JPMorgan Chase (JPM) and United Airlines (UAL). The report did not establish a common cause connecting those incidents. The distinction matters. A cluster of outages can increase concern about digital infrastructure reliability without proving a coordinated attack or a shared technical failure. For businesses, the immediate issues are service continuity, recovery time and customer trust.

SELLAS Surges Following Phase 3 Leukemia Trial Results

SELLAS Life Sciences Group (SLS) supplied one of the day’s most dramatic company-specific developments. The supplied market report described a roughly 240% share-price surge following positive Phase 3 REGAL trial results. That percentage was a reported trading move, not a verified closing return. According to the company’s announcement, its investigational cancer vaccine galinpepimut-S met the trial’s primary overall-survival endpoint in a defined population of patients with acute myeloid leukemia. The reported findings included:

  • Median overall survival of 24.0 months with treatment versus 14.7 months with best available treatment.
  • A hazard ratio of 0.59, corresponding to a 41% reduction in the estimated hazard of death during the study.
  • A two-sided p-value of 0.035.
  • No new safety signals identified in the topline analysis

The trial involved patients in a second or later remission following salvage therapy who were unable or ineligible to undergo an allogeneic stem-cell transplant. Those eligibility criteria matter because the findings should not be generalized to every patient with acute myeloid leukemia. The results represent a clinical milestone, not regulatory approval. Additional analyses, regulatory review and any eventual commercialization remain separate steps.

What Tuesday’s Market Means

Tuesday’s decline reflected a market facing several overlapping tests rather than a single isolated headline. Consumer spending continued to grow, but inflation-adjusted strength was less clear. Import prices added to concern about persistent cost pressure. Williams’ comments argued against an outsized rate move without removing the possibility of further tightening. Meanwhile, Nvidia’s (NVDA) pending earnings and Anthropic’s proposed offering kept attention on whether AI expectations can translate into sustainable business performance The closing pattern captured that uncertainty: all four major equity benchmarks declined, small caps remained under pressure, and volatility increased sharply. For many, the next test is whether earnings growth and credible guidance can offset an interest-rate environment that remains demanding for equity valuations

Updates From the VP Watchlist

Amwell® (NYSE: AMWL)

Amwell® (NYSE: AMWL), a leading provider of technology-enabled care, closed at $11.20. Amwell reported after the close Nov. 3 the company’s Third Quarter 2026 Highlights: Recorded Total Revenue of $49.0 million, exceeding the previously provided financial guidance range for Q3, Achieved subscription revenue of $23.9 million, Recorded Amwell Medical Group (“AMG”) visit revenue of $23.7 million, Reported gross margin of 53%, Net loss was ($11.0) million, compared to ($9.6) million in the second quarter of 2026, Adjusted EBITDA of ($3.6) million compared to ($1.2) million in the second quarter of 2026, & Total visits on the platform were 0.8 million. Financial Outlook: The Company is raising its 2026 revenue outlook, and adjusted EBITDA outlook, and reaffirming its AMG visit guidance., Revenue in the range of $204 million to $206 million increased from $200 million to $205 million. AMG visits between 1.32 million and 1.37 million Adjusted EBITDA in the range between ($8) million to ($7) million increased from ($9) million to ($7) million.

The Company also provided financial guidance for Q4 2026 Revenue and adjusted EBITDA:

  • Q4 revenue in the range of $48 million to $50 million
  • Q4 adjusted EBITDA expected to in the range of $0 million to $1 million.

The Company also reiterated its objective to achieve positive cash flow from operations in the fourth quarter of 2026.

Serina Therapeutics (NYSE: SER)

Serina Theraeuptics (NYSE: SER, $1.365) is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ PlatformTM provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology.

On Thursday, November 12, Serina reported its financial results for the third quarter ended September 30, 2026, along with key business updates. Steve Ledger, Chief Executive Officer of Serina stated, “We are excited about the achievement of important clinical milestones for SER-252 in Parkinson’s disease, advancing from the initial evaluation of our lowest-dose cohort into the next stage of dose escalation. Importantly, the blinded pharmacokinetic observations from Cohort 1 showed the sustained drug exposure SER-252 was designed to achieve, and the independent Safety Monitoring Committee recommended proceeding with continued development. Dosing in Cohort 2 is currently underway and focuses on demonstrating SER-252’s potential as a differentiated treatment option for patients with advanced Parkinson’s disease to improve the significant challenge of consistent symptom control.”

On Thursday, September 24, 2026, Serina CEO Steve Ledger discussed discuss Serina’s programs’ progress during Tribe Public’s “A New Approach to Advanced Parkinson’s Disease: Serina Discusses SER-252’s Clinical Progress”webinar, followed by a live Q&A. You may view it below.

Eupraxia Pharmaceuticals Inc. (EPRX)

Eupraxia Pharmaceuticals Inc. (EPRX, $6.62), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today, ( Nov. 10), announced its financial results for the third quarter of 2026. Dr. James A. Helliwell, Chief Executive Officer of Eupraxia stated, “We remain on track to report interim results from the Phase 2b portion of the RESOLVE trial in December, and were pleased to announce in mid-October that we had reached our target enrollment of 120 patients. We are very encouraged by the Phase 1b/2a data from the open-label portion of the RESOLVE trial that was reported this quarter, which includes 36- and 52-week data from our highest dosing cohorts. We believe this data provides further evidence of the observed durable treatment effects of EP-104GI in EoE patients, seen in previous cohorts. In total, we have observed 64% of patients remaining in clinical remission over this 52-week period in addition to clinically meaningful histologic improvements. With cash runway into the second half of 2028, we believe we remain well funded to execute on our upcoming milestones for our EoE program.”

EPRX gained a significant new Wall Street endorsement Monday as RBC Capital Markets initiated coverage with an Outperform rating, a Speculative Risk designation and a $14 price target. The research makes a bullish case for EP-104GI, the company’s investigational treatment for eosinophilic esophagitis, ahead of an expected December clinical readout. Against the $6.89 reference price in RBC’s report, the target implies approximately 103% upside, not a forecast of where shares must trade. The attraction is unusually straightforward for biotechnology: take a familiar anti-inflammatory medicine, deliver it precisely into diseased tissue and attempt to make its benefits last long enough to change the treatment routine. If that approach succeeds, Eupraxia would offer more than another prescription for a chronic disease. It could offer a different calendar. RBC analyst Douglas Miehm’s November 9 initiation argues that EP-104GI could occupy a differentiated position in eosinophilic esophagitis, commonly called EoE, through localized delivery and the potential for once-yearly administration. The next major test is whether encouraging early results translate into convincing evidence against a vehicle control in the Phase 2b RESOLVE study.

EPRX announced (Oct. 15) that the ongoing RESOLVE study evaluating the safety and efficacy of EP-104GI for the treatment of Eosinophilic Esophagitis (“EoE”) has reached its enrollment target. “This is a significant milestone for the RESOLVE trial and the development of EP-104GI as a potential treatment option in EoE” said Dr. James Helliwell, Chief Executive Officer of Eupraxia. “We look forward to our interim analysis in December where we will be reporting on symptoms, histologic findings and safety in the first 60 patients in Phase 2b to reach 6 months. Data will also be available on the patients at 3, 9- and 12-month timepoints giving a fulsome interim look at the RESOLVE Trial”.

Modular Medical, Inc. (NASDAQ: MODD)

Modular Medical, Inc. (NASDAQ: MODD, $1.80), a commercial-stage medical device company preparing for the full commercial launch of its next-generation Pivot™ tubeless patch pump, is pursuing a different proposition: make insulin delivery less demanding for the people who must manage it every day. New patient research announced November 9 gives that strategy a persuasive commercial foundation. In a three-phase study conducted with Thrivable involving more than 540 people with Type 1 or Type 2 diabetes, approximately nine out of 10 surveyed multiple daily injection users said they would consider a simpler insulin delivery option. In the final-phase survey of 303 participants, 48.5% expressed strong interest in the company’s Pivot tubeless patch pump. The distinction matters. General enthusiasm for something easier is not the same as product-specific interest, and neither is a prescription. Still, the findings suggest Modular Medical is addressing a recognizable problem rather than inventing one for the benefit of a presentation deck. For many following MODD, the emerging opportunity centers on one word: simplicity. The company has already moved beyond the purely developmental stage. Its annual report documents U.S. Food and Drug Administration clearance for Pivot in April 2026, followed by commercial availability and initial patient shipments in June. The question now is whether a differentiated product, improving access and more focused patient education can turn that regulatory foundation into a repeatable commercial business.

MODD announced (Oct. 27) that it has received a positive decision from its notified body regarding certification of its quality management system under ISO 13485:2016. The notified body is designated under the European Union Medical Device Regulation (“MDR”).

MODD CEO, Jeb Besser, co-hosted a Tribe Public’s CEO Presentation and Q&A Webinar Event titled “The Road To Revenue: Modular Medical’s Strategy For Launching Pivot,” that was held Friday, September 4, 2026.. You may watch the event video below now if you missed it below now.

Alphabet (NASDAQ: GOOGL $280.20, -1.24%)

Alphabet (NASDAQ: GOOGL, GOOG) is confronting an expensive paradox: Artificial intelligence is bringing more activity to Google while making the economics of that activity harder to predict. Yet the latest results offer a more constructive interpretation than a simple obituary for search. Third-quarter revenue increased 25% to $127.6 billion. Operating income climbed 30% to $40.6 billion. Google Cloud revenue more than doubled. Those are unusual credentials for a company supposedly being escorted toward technological irrelevance. At the close on Thursday, Alphabet shares traded at $283.82, following a 12.64% decline, many are clearly demanding more proof and fewer architectural renderings of future data centers. That skepticism is understandable. But the opportunity lies in distinguishing a difficult transition in monetization from a collapse in demand. Google’s problem is not that people have stopped asking questions. According to management, its year-over-year search-query growth reached its highest rate in five years during the third quarter. The more consequential question is how quickly Google can turn its expanding AI audience into attractive, durable cash flow. Wall Street has little patience for a renovation when the contractor’s estimate begins with a trillion.

Space Exploration Technologies Corp. (SPCX, $141.70, +3.18%)

SpaceX-related coverage is orbiting three themes: a possible combination with Tesla, an expanding AI infrastructure footprint, and robust Starlink demand, because apparently conquering one industry at a time is inefficient. Reported third-quarter revenue totaled $14.6 billion, while management projected first-quarter 2027 revenue of $33 billion–$37 billion, a range with little apparent interest in remaining earthbound. The latest reporte

The Sources

  1. November 17 market session and Nvidia earnings setup
  2. Nvidia fiscal third-quarter earnings preview
  3. Anthropic proposed IPO pricing and listing timetable
  4. Walt Disney cash dividend announcement
  5. Disney earnings, streaming profitability and reporting changes
  6. John Williams’ comments on December interest-rate policy
  7. SELLAS share-price reaction to REGAL trial results
  8. Apple service disruptions and other technology outages
  9. Microsoft Ignite announcements and enterprise AI costs
  10. U.S. Census Bureau: October 2026 retail sales
  11. U.S. Bureau of Labor Statistics: October 2026 import and export prices
  12. Bloomberg: Williams pushes back on a dramatic rate move
  13. SELLAS Life Sciences Group: Phase 3 REGAL topline results

Disclosure: This article is for informational purposes only and should not be construed as investment advice, a recommendation, or an offer to buy or sell any security. Market data are subject to revision, and investors should conduct independent due diligence before making investment decisions. Investments may involve substantial risk, including the potential loss of the entire investment. Investors should conduct independent due diligence and consider their individual objectives and risk tolerance. See The Complete Disclosure via this link & at the top of the page.